Dynavax Technologies Corporation (DVAX)

Market Cap	1.60B
Revenue (ttm)	260.81M
Net Income (ttm)	20.48M
Shares Out	131.45M
EPS (ttm)	0.15
PE Ratio	80.53
Forward PE	40.23
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,307,380
Open	12.01
Previous Close	12.01
Day's Range	11.75 - 12.24
52-Week Range	9.74 - 15.01
Beta	1.34
Analysts	Buy
Price Target	22.00 (+80.77%)
Earnings Date	Nov 7, 2024

About DVAX

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, In...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 19, 2004
• Employees: 408
• Stock Exchange: NASDAQ
• Ticker Symbol: DVAX
• Website: https://www.dynavax.com

Analyst Forecast

According to 2 analysts, the average rating for DVAX stock is "Buy." The 12-month stock price forecast is $22.0, which is an increase of 80.77% from the latest price.

Price Target

$22.0

(80.77% upside)

Analyst Consensus: Buy